was linked to circadian disruption and insomnia severity in cancer survivors with insomnia.
Evidence
This biomarker analysis used blood RNA-sequencing from cancer survivors with insomnia in the YOCAS-II trial and compared BloodCCD scores with healthy individuals and insomnia severity patterns across intervention arms.
Caveat
The findings are correlational, and the abstract does not report sample size, effect sizes, or whether BloodCCD changed with yoga, CBT-I, or placebo treatment.
METHODS: BloodCCD was developed to biochemically assess circadian rhythms in blood. It was adapted from the previously published Clock Correlation Distance (CCD) and uses a correlation matrix of 42 genes known to oscillate throughout the day in blood.
RESULTS: Cancer survivors had higher (worse) BloodCCD scores, indicating disrupted circadian clock, compared to healthy individuals. Furthermore, insomnia severity correlated with worse BloodCCD, and those in the YOCAS and behavioral placebo arm showed significant correlation between BloodCCD score and insomnia.
CONCLUSIONS: BloodCCD shows promise as a biomarker to biochemically detect disrupted circadian rhythms in cancer survivors, and as an indicator for insomnia severity.
CLINICAL TRIAL IDENTIFIER: NCT02613364.
Key numbers
9
Score Increase
scores for severe insomnia patients
8.24
Score Comparison
scores for moderate insomnia patients
7.94
Score for Subthreshold Insomnia
scores for subthreshold insomnia patients
Full Text
We can’t show the full text here under this license.
Circadian Biology